 |
|
Auditory Effects After Organ Preservation Protocol for Laryngeal/Hypopharyngeal Carcinomas
Patricia Helena Pecora Liberman;
Christiane Schultz;
M. Valéria Schmidt Goffi Gomez, PhD;
André Lopes Carvalho, MD, PhD;
Antonio Cassio Assis Pellizzon, MD;
José Ricardo Testa, MD, PhD;
Olavo Feher, MD;
Luiz Paulo Kowalski, MD, PhD
Arch Otolaryngol Head Neck Surg. 2004;130:1265-1268.
Objective To investigate the prevalence of hearing loss after concomitant radiochemotherapy in patients enrolled in a larynx preservation protocol.
Design Prospective study.
Setting Consecutive patients treated in a tertiary cancer center hospital between 2001 and 2002.
Patients Eligible subjects included patients prospectively enrolled in an organ preservation protocol based on concomitant radiotherapy and chemotherapy (cisplatin and paclitaxel).
Main Outcome Measures Descriptive analysis of the results of audiologic evaluations, including pure-tone audiometry and immitance audiometry, which were performed prior to and 8 months after treatment. Change in hearing sensitivity was computed relative to baseline measures. Criteria to indicate hearing decrease after the treatment were defined as either a 20-dB decrease at any single test frequency or a 10-dB decrease at any 2 adjacent test frequencies.
Results A total of 11 patients were analyzed. Four patients (36%) had hearing loss after the treatment.
Conclusion Our results suggest that the prevalence of hearing loss after radiochemotherapy in larynx preservation protocols is high (36%); however, it was usually mild and asymptomatic.
Author Affiliations: Departments of Audiology (Mss Liberman and Schultz and Dr Gomez), Head and Neck Surgery and Otorhinolaryngology (Drs Carvalho, Testa, and Kowalski), Radiotherapy (Dr Pellizzon), and Oncology (Dr Feher), Hospital do Câncer A.C. Camargo, São Paulo, Brazil. Dr Feher is now in private practice in São Paulo.
|
